Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
A proposed experiment using underground laboratory space would isolate the contribution of muon radiation to epigenetic aging by comparing cell cultures grown in radiation-depleted versus surface conditions. This addresses a fundamental gap in aging research: quantifying how much age-related damage stems from unavoidable external radiation versus internal biological processes.
Regulatory agencies and longevity developers are converging on pragmatic pathways that sidestep philosophical debates about aging's classification. The shift toward validated clinical outcome assessments and intrinsic capacity frameworks signals the field's transition from biomarker entertainment to demonstrable human benefit—the actual barrier to therapeutic approval.
A 18-year partnership between UCL and Eisai—extended through 2030—demonstrates that sustained institutional collaboration in neuroscience drug discovery outperforms the typical transactional model. Continuity in funding and leadership, rather than speed, may be essential for solving complex neurodegeneration problems like Alzheimer's and Parkinson's disease.
LET-607, a transcription factor in C. elegans, enforces a trade-off between two protein-quality control systems—suppressing cytosolic stress response while promoting endoplasmic reticulum stress response. Removing LET-607 rebalances this allocation, enhancing cytosolic protein quality control and extending lifespan, suggesting that developmental optimization sacrifices longevity potential.
Haut.AI has launched an AI-powered platform that analyzes skin across the entire body—not just the face—to provide quantitative measurements and personalized product recommendations. The technology was trained on over 100,000 skin images across all skin types and validated for clinical accuracy, addressing a market gap where 80% of consumers report pressure to maintain healthy-looking skin.
Alterity Therapeutics received FDA alignment on a registrational pathway for ATH434 in multiple system atrophy, with a single pivotal Phase 3 trial expected to support New Drug Application filing. The drug targets iron accumulation and alpha-synuclein pathology, with enrollment planned for late 2026.
Nanoscope Therapeutics and Catalent have established manufacturing and commercial supply infrastructure for MCO-010, an optogenetic gene therapy designed to restore vision in retinitis pigmentosa and Stargardt disease by reprogramming retinal cells to sense light. Positive Phase 2b/3 data support progression toward regulatory approval, with Phase 3 trials planned for 2026.
BlueRock Therapeutics and RoslinCT have partnered to expand access to clinical-grade induced pluripotent stem cell lines, enabling cell therapy developers to conduct research, process development, and manufacturing at scale. This partnership accelerates the pathway from early-stage evaluation to clinical and commercial production for regenerative cell therapies.
A regulatory RNA molecule specific to immune T cells sustains metabolic balance and immune function in the aging liver, addressing a fundamental mechanism of age-related decline. This correction validates findings on how the body maintains coordinated immune and metabolic signaling during aging.
Current UK health guidelines establish bare-minimum thresholds for physical activity and protein intake designed to prevent deficiency, not optimize healthspan. Evidence demonstrates substantially higher levels of activity and protein consumption correlate with meaningfully reduced mortality risk and preserved physical independence across the lifespan.
The seventh Longevity Investors Conference convenes leading geroscientists, entrepreneurs, and institutional investors in Gstaad to examine which longevity therapies will attract capital and reach clinical deployment. The event reflects the sector's maturation from early-stage hypothesis generation toward translational execution and scaled healthcare integration.
A year-long home-based study of 119 participants demonstrates that individuals with mild Alzheimer's disease can reliably self-administer frequent brain health assessments using a wireless EEG headset and cognitive task platform, achieving 99.7% completion rates and generating high-frequency data that may accelerate clinical trial design and reduce costs.